Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling

[1]  U. Brinkmann.  CAS, the human homologue of the yeast chromosome-segregation gene CSE1, in proliferation, apoptosis, and cancer. , 1998, American journal of human genetics.

[2]  C. Bose,et al.  Enzymatic tumour markers in ovarian cancer: a multiparametric study. , 1994, Cancer letters.

[3]  S. Henderson,et al.  Predicting biomarkers for ovarian cancer using gene-expression microarrays , 2004, British Journal of Cancer.

[4]  H. Brustmann.  Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study. , 2004, Gynecologic oncology.

[5]  U. Löhrs,et al.  CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. , 2002, American journal of clinical pathology.

[6]  F. Balkwill,et al.  Hypoxia down‐regulates MCP‐1 expression: implications for macrophage distribution in tumors , 1998, Journal of leukocyte biology.

[7]  T. Tamaya,et al.  Expression of E-cadherin and α- and β-catenin mRNAs in ovarian cancers , 1997 .

[8]  G. Tulunay,et al.  Significance of Serum and Peritoneal Fluid Lactate Dehydrogenase Levels in Ovarian Cancer , 2000, Gynecologic and Obstetric Investigation.

[9]  R. Roden,et al.  A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Jeffrey R Marks,et al.  Gene Expression Patterns That Characterize Advanced Stage Serous Ovarian Cancers , 2004, The Journal of the Society for Gynecologic Investigation: JSGI.

[11]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Y. Denoux,et al.  Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. , 1996, Gynecologic oncology.

[14]  H Strohmaier,et al.  A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. , 2001, Molecular cell.

[15]  S. Mok,et al.  Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. , 2001, BioTechniques.

[16]  T. Hudson,et al.  Characterization of variability in large-scale gene expression data: implications for study design. , 2002, Genomics.

[17]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[18]  G. Stamp,et al.  The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. , 1995, The Journal of clinical investigation.

[19]  J. Kononen,et al.  Cyclin E overexpression and amplification in human tumours , 2003, The Journal of pathology.

[20]  Michele Pagano,et al.  Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma , 2004, Cancer.

[21]  R. Berkowitz,et al.  Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.

[22]  E. Kohn,et al.  The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects. , 1996, Gynecologic oncology.

[23]  Mitsuaki Suzuki,et al.  Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma , 2003, Cancer.

[24]  V. Turk,et al.  Stefin B, the major low molecular weight inhibitor in ovarian carcinoma. , 1994, Cancer letters.

[25]  B. Ślesak,et al.  Immunological reactivity of mucinous and serous ovarian adenocarcinomas. , 1986, Cancer detection and prevention.

[26]  K. Shigemasa,et al.  Cyclin E mRNA Overexpression in Epithelial Ovarian Cancers: Inverse Correlation with p53 Protein Accumulation , 2001, The Journal of the Society for Gynecologic Investigation: JSGI.

[27]  C. Romanini,et al.  Cisplatin‐based polychemotherapy reduces the natural cytotoxicity of peripheral blood mononuclear cells in patients with advanced ovarian carcinoma and their in vitro responsiveness to interleukin‐12 incubation , 1999, Cancer.

[28]  R. Berkowitz,et al.  Osteopontin as a potential diagnostic biomarker for ovarian cancer. , 2002, JAMA.

[29]  R. Zeillinger,et al.  Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors , 1996, International journal of cancer.

[30]  G. Heinze,et al.  Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients , 1999, British Journal of Cancer.

[31]  B. Davidson,et al.  Borderline tumors of the ovary , 1998, Cancer.

[32]  M. Friedlander,et al.  Prognostic factors in ovarian cancer. , 1992, Seminars in oncology.

[33]  Anne-Marie Mes-Masson,et al.  Signature of a silent killer: expression profiling in epithelial ovarian cancer , 2004, Expert review of molecular diagnostics.

[34]  Worsley,et al.  Expression of E‐cadherin, α‐catenin and β‐catenin in normal ovarian surface epithelium and epithelial ovarian cancers , 1998 .

[35]  H. Liapis,et al.  Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). , 1998, Human pathology.

[36]  J. Baak,et al.  Correlation between nuclear DNA content and steroid receptor status in ovarian cancer. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[37]  Anne-Marie Mes-Masson,et al.  Microarray analysis of gene expression mirrors the biology of an ovarian cancer model , 2001, Oncogene.

[38]  G. Goodman,et al.  Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Hixon,et al.  Loss of Mitotic Spindle Checkpoint Activity Predisposes to Chromosomal Instability at Early Stages of Fibrosarcoma Development , 2003, Cell cycle.

[40]  I. Bukovsky,et al.  Peritoneal fluid lactate dehydrogenase in ovarian cancer. , 1997, Gynecologic oncology.

[41]  R. L. Baldwin,et al.  Gene expression in epithelial ovarian carcinoma , 2002, Oncogene.

[42]  J. Baak,et al.  The management of borderline epithelial tumors of the ovary. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[43]  F. Bischoff,et al.  Export of Importin α from the Nucleus Is Mediated by a Specific Nuclear Transport Factor , 1997, Cell.

[44]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[45]  L. Hood,et al.  Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. , 1999, Gene.

[46]  B. Davis,et al.  Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. , 2004, Gynecologic oncology.

[47]  H. Yee,et al.  Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. , 2001, Human pathology.

[48]  K. Takagishi,et al.  Overexpression of autocrine motility factor in metastatic tumor cells: possible association with augmented expression of KIF3A and GDI-β , 2004, Laboratory Investigation.

[49]  I. Shih,et al.  Mutational Analysis of K-ras Segregates Ovarian Serous Carcinomas into Two Types: Invasive MPSC (Low-grade Tumor) and Conventional Serous Carcinoma (High-grade Tumor) , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[50]  J. Barrett,et al.  Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. , 2002, Gynecologic oncology.

[51]  A. Blaustein,et al.  Tumor markers in inclusion cysts of the ovary , 1982, Cancer.

[52]  K. Milde-Langosch,et al.  Expression and Prognostic Value of the Cell-cycle Regulatory Proteins, Rb, p16MTS1, p21WAF1, p27KIP1, Cyclin E, and Cyclin D2, in Ovarian Cancer , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[53]  V. Turk,et al.  Cystatins and stefins in ascites fluid from ovarian carcinoma. , 1992, Cancer letters.

[54]  D. Katsaros,et al.  The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. , 2003, Experimental cell research.

[55]  S. Reed,et al.  Cks1-dependent proteasome recruitment and activation of CDC20 transcription in budding yeast , 2003, Nature.

[56]  Shuk-Mei Ho,et al.  Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells , 1999 .

[57]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[58]  J. Gu,et al.  Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. , 2001, Journal of the National Cancer Institute.

[59]  R. Kurman,et al.  Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. , 2000, Human pathology.

[60]  M. Dietel,et al.  Serous tumors of low malignant potential of the ovary , 2000, Virchows Archiv.

[61]  Y. Dong,et al.  Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. , 2001, Gynecologic oncology.

[62]  P. Leung,et al.  Ovarian surface epithelium: biology, endocrinology, and pathology. , 2001, Endocrine reviews.

[63]  A. Bellacosa,et al.  Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression , 1998, International journal of cancer.

[64]  Russ B. Altman,et al.  Nonparametric methods for identifying differentially expressed genes in microarray data , 2002, Bioinform..

[65]  J. Felix,et al.  Potential role of the inactivated X chromosome in ovarian epithelial tumor development. , 1996, Journal of the National Cancer Institute.

[66]  G. Yousef,et al.  Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin. , 2003, Clinical chemistry.

[67]  M. Kitagawa,et al.  High expression of Cks1 in human non-small cell lung carcinomas. , 2003, Biochemical and biophysical research communications.

[68]  P Zola,et al.  Overexpression of the MET/HGF receptor in ovarian cancer , 1994, International journal of cancer.

[69]  Roger E Bumgarner,et al.  Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. , 1999, Gene.

[70]  R. Kurman,et al.  Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors) , 2002, Cancer.

[71]  M. Schummer,et al.  Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q , 2003, International journal of cancer.

[72]  A. Mes-Masson,et al.  Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. , 1994, Experimental cell research.

[73]  T. Hudson,et al.  Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines , 2003, Oncogene.

[74]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[75]  L. Sui,et al.  The Concurrent Expression of p27kip1and Cyclin D1 in Epithelial Ovarian Tumors , 1999 .

[76]  E. Kohn,et al.  Borderline ovarian tumors. , 1996, The American journal of medicine.

[77]  V. Kosma,et al.  Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[79]  A. Skubitz,et al.  Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells , 2004, Clinical & Experimental Metastasis.

[80]  Isabelle Camby,et al.  Galectins and cancer. , 2002, Biochimica et biophysica acta.

[81]  T. Caputo,et al.  Cell‐free 27 kDa heat shock protein (hsp27) and hsp27–cytochrome c complexes in the cervix of women with ovarian or endometrial cancer , 2002, International journal of cancer.

[82]  Stephen J. Williams,et al.  Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. , 2002, DNA and cell biology.

[83]  B. Slotman,et al.  Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator , 1990, Cancer.

[84]  T. Hudson,et al.  Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. , 2002, Genome research.

[85]  J. Harper,et al.  Protein destruction: Adapting roles for Cks proteins , 2001, Current Biology.

[86]  I. Shih,et al.  Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. , 2003, Journal of the National Cancer Institute.

[87]  A. Ayhan,et al.  Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. , 2001, European journal of gynaecological oncology.

[88]  I. Nagata,et al.  Preoperative Determination of Several Serum Tumor Markers in Patients with Primary Epithelial Ovarian Carcinoma , 1999, Gynecologic and Obstetric Investigation.

[89]  J. Nesland,et al.  E‐cadherin and α‐, β‐, and γ‐catenin protein expression is up‐regulated in ovarian carcinoma cells in serous effusions , 2000 .

[90]  A. Kumagai,et al.  The Xenopus Suc1/Cks Protein Promotes the Phosphorylation of G2/M Regulators* , 1999, The Journal of Biological Chemistry.

[91]  P. V. van Diest,et al.  T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. , 2001, European journal of obstetrics, gynecology, and reproductive biology.